
NanoViricides Reports Significant Progress in Measles Treatment with NV-387
NanoViricides, Inc. announces promising results for its lead drug candidate NV-387 in treating Measles, showing a 130% increase in survival in humanized mice, highlighting the potential for the first therapeutic option against the virus amidst rising global cases.
Read full story


























